UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on HCP
In a report published Friday, Jefferies & Company reiterated its Hold rating on HCP (NYSE: HCP), and slightly raised its price target from $45.00 to $46.00.
Jefferies noted, “We are updating our estimates for HCP and AMRE following announcements during the NAREIT conference in San Diego, CA. Our price target for HCP also increases to $46 from $45. See our accompanying note entitled ‘Tweets from NAREIT (November 2012 Edition)'.”
HCP closed on Thursday at $43.78.
Latest Ratings for HCP
|Jan 2017||Goldman Sachs||Upgrades||Neutral||Buy|
|Dec 2016||BMO Capital||Upgrades||Underperform||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.